Volume 20, number 4
 PDF Downloads: 90

Association of Alu APO Gene Marker with Type 2 Diabetic patients of Dimapur District, Nagaland India

Semsadangla Ao1, Moamenla Singson2 and Jeyaparvathi Somasundaram1*

1Department of Zoology, St Joseph University, Chumoukedima, Nagaland, India.

2Eden Medical Centre, Dimapur, Nagaland, India.

Corresponding Author E-mail:jeya5001@gmail.com

DOI : http://dx.doi.org/10.13005/bbra/3193

ABSTRACT: With Type 2 Diabetes, the body either produces insufficient insulin or rejects it, which leads to an accumulation of glucose in the blood. Type 2 diabetes affects 90% of the population.. Examining the relationship between Type 2 diabetes patients from the tribal tribes of Dimapur District and the Alu APO gene marker was the main goal of this study. Using the use of random sampling, blood samples were taken from 31 Type 2 Diabetes Mellitus  patients at Eden Medical Centre in Dimapur and 31 control samples were collected from healthy individuals .  Depending on the patient availability, blood samples were taken from both male and female patients. Within a day of collecting the blood, DNA was extracted. PCR and an allele-specific marker (APO) were used for genotyping. After genotyping, results were recorded by visualizing the PCR products in UV transilluminator. With this investigation, we discovered that the female exhibits a high statistical significance in the DD genotype (0.00*). On the other hand, neither genotype is statistically significant in males.

KEYWORDS: APO gene; Dimapur; Insulin; PCR; Type 2 Diabetes

Download this article as: 
Copy the following to cite this article:

Ao S, Singson M, Somasundaram J. Association of Alu APO Gene Marker with Type 2 Diabetic patients of Dimapur District, Nagaland India. Biotech Res Asia 2023;20(4).

Copy the following to cite this URL:

Ao S, Singson M, Somasundaram J. Association of Alu APO Gene Marker with Type 2 Diabetic patients of Dimapur District, Nagaland India. Biotech Res Asia 2023;20(4). Available from: https://bit.ly/3ux4ndG

[ HTML Full Text]

Back to TOC